CRC Scotland & London, SW1V 1PG London, UK.
Front Biosci (Landmark Ed). 2023 Dec 28;28(12):355. doi: 10.31083/j.fbl2812355.
Alzheimer's disease is widely regarded as poorly treated due to poor conceptualization. For 40 years, Alzheimer's disease pathophysiology has focused on two culprits, amyloid-β induced plaques and hyperphosphorylated tau associated tangles, with no significant treatment advance. This is confounded by data showing amyloid-β to be an endogenous antimicrobial that is increased in a wide array of diverse medical conditions associated with heightened inflammation. This article reviews the wider bodies of data pertaining to Alzheimer's disease pathophysiology, highlighting the role of suppressed astrocyte mitochondrial function and mitochondrial melatonergic pathway as a core hub in driving neuronal loss in dementia. It is proposed that astrocyte function over aging becomes dysregulated, at least partly mediated by systemic processes involving the 10-fold decrease in pineal melatonin leading to the attenuated capacity of night-time melatonin to dampen residual daytime inflammation. Suppressed pineal melatonin also attenuates melatonin's inhibition of glucocorticoid receptor nuclear translocation, thereby changing not only stress/hypothalamus-pituitary-adrenal (HPA) axis consequences but also the consequences of the cortisol awakening response, which 'primes the body for the coming day'. Gut microbiome-derived butyrate also inhibits glucocorticoid receptor nuclear translocation, as well as inducing the mitochondrial melatonergic pathway. It is proposed that the loss of astrocyte melatonin prevents the autocrine and paracrine effects of melatonin in limiting amyloid-β levels and effects. Suppressed astrocyte melatonin production also attenuates the melatonin induction of astrocyte lactate, thereby decreasing neuronal mitochondrial metabolism and the neuronal mitochondrial melatonergic pathway. The loss of astrocyte lactate and melatonin, coupled to the suppression of neuronal mitochondrial metabolism and melatonin production decreases mitophagy, leading to the induction of the major histocompatibility complex (MHC)-1. MHC-1 initiates the chemoattraction of CD8+ t cells, leading to neuronal destruction in Alzheimer's disease being driven by 'autoimmune'/'immune-mediated' processes. Alzheimer's disease may therefore be conceptualized as being initiated by systemic processes that act on astrocytes as a core hub, with the suppression of the astrocyte melatonergic pathway leaving neurons deplete of appropriate metabolic substrates and co-ordinated antioxidants. This culminates in an 'immune-mediated' cell death. Future research and treatment/prevention implications are indicated.
阿尔茨海默病被广泛认为治疗效果不佳,这是由于对其发病机制的概念理解不足。四十年来,阿尔茨海默病的病理生理学研究一直集中在两个罪魁祸首上,即淀粉样β诱导的斑块和过度磷酸化的 tau 相关缠结,但没有显著的治疗进展。这与数据相矛盾,数据表明淀粉样β是一种内源性抗菌物质,在与炎症加剧相关的广泛多样的医疗条件下都会增加。本文综述了与阿尔茨海默病病理生理学相关的更广泛的数据,强调了星形胶质细胞线粒体功能和线粒体褪黑素途径受到抑制作为导致痴呆神经元丢失的核心枢纽的作用。有人提出,随着年龄的增长,星形胶质细胞功能失调,至少部分是由涉及松果腺褪黑素减少 10 倍的全身性过程介导的,导致夜间褪黑素抑制残留日间炎症的能力减弱。松果腺褪黑素的抑制也减弱了糖皮质激素受体核易位,从而不仅改变了应激/下丘脑-垂体-肾上腺 (HPA) 轴的后果,还改变了皮质醇觉醒反应的后果,使身体为即将到来的一天做好准备。肠道微生物组衍生的丁酸盐也抑制糖皮质激素受体核易位,并诱导线粒体褪黑素途径。有人提出,星形胶质细胞褪黑素的丧失阻止了内源性和旁分泌作用,限制了淀粉样β水平和作用。星形胶质细胞褪黑素产生的抑制也减弱了褪黑素诱导的星形胶质细胞乳酸,从而降低神经元线粒体代谢和神经元线粒体褪黑素途径。星形胶质细胞乳酸和褪黑素的丧失,加上神经元线粒体代谢和褪黑素产生的抑制,导致自噬减少,从而诱导主要组织相容性复合体 (MHC)-1 的诱导。MHC-1 启动 CD8+T 细胞的化学吸引,导致阿尔茨海默病中的神经元破坏由“自身免疫”/“免疫介导”过程驱动。因此,阿尔茨海默病可以被概念化为由作用于星形胶质细胞作为核心枢纽的系统性过程引发的,星形胶质细胞褪黑素途径的抑制使神经元缺乏适当的代谢底物和协调的抗氧化剂。这最终导致“免疫介导”的细胞死亡。指出了未来的研究和治疗/预防意义。